Credits Available: 4.25 AMA PRA Category 1 Credits™, 4.25 ANCC Contact Hours, 4.25 ACPE

Description: This dynamic curriculum, detailed by a specialty center clinician, explores each of the CD 19-directed CAR T-cell therapies available for the treatment of DLBCL; solutions to referral and logistic challenges; in-depth early and late toxicity management in CAR T-cell treatment; and the delivery of goal-concordant care using shared decision-making strategies. A challenging real-world case scenario discussion within each Gather-ed group highlights critical decision points, key challenges, and opportunities to incorporate collective insights.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Pharmacist, Physician Assistant, Nurse, Pharmacy Director
Target Specialties: Hematology, Hematology/Oncology, Oncology

Reem Karmali

Northwestern University, Feinberg School of Medicine

Dr. Karmali’s overarching goal is to improve outcomes for patients with lymphoma though practice and research. Her clinical research focuses on identifying novel targets for drug design and development including cellular therapies. Her translational research explores on the role of metabolic dysregulation in lymphomagenesis and resistance to therapy. She has published widely, authoring more than 100 peer-reviewed journal articles.